Dalteparin Sodium (Fragmin®): A Comprehensive Pharmacological and Clinical Monograph

Introduction and Drug Identification

Overview of Dalteparin as a Low Molecular Weight Heparin (LMWH)

Dalteparin is a potent antithrombotic agent belonging to the class of low molecular weight heparins (LMWHs). It is a biological product derived from unfractionated heparin (UFH) of porcine intestinal mucosa origin through a controlled process of nitrous acid depolymerization.[1] This process yields a complex mixture of strongly acidic sulphated polysaccharide chains with an average molecular weight of approximately 5000 Daltons; about 90% of the material falls within the 2000 to 9000 Dalton range.[1] The resulting product, dalteparin sodium, functions as an anticoagulant, commonly referred to as a "blood thinner," and is clinically utilized for the prophylaxis and treatment of thromboembolic disorders, including deep vein thrombosis (DVT) and pulmonary embolism (PE).[3]

Marketed globally under the brand name Fragmin®, dalteparin holds a significant place in modern antithrombotic therapy.[3] Its development represented a substantial advancement over its parent compound, UFH. Dalteparin exhibits several key advantages, including a more predictable pharmacokinetic profile, superior bioavailability following subcutaneous administration, and a longer biological half-life. These properties permit reliable weight-based dosing, typically via self-administered subcutaneous injection, and reduce or eliminate the need for the intensive laboratory monitoring required for UFH therapy.[1] In recognition of its efficacy, safety, and critical role in healthcare, dalteparin is included on the World Health Organization's List of Essential Medicines.[3]

Key Identifiers and Chemical Properties

Precise identification of dalteparin is essential for clinical, research, and regulatory purposes. As a small molecule biological product, it is characterized by a range of identifiers that distinguish it from other heparins and anticoagulants.[2] The active pharmaceutical ingredient is the sodium salt of dalteparin.[6] The following table consolidates its key identifiers.

Table 1: Dalteparin Identification Summary

Identifier	Value(s)	Source(s)
Drug Name	Dalteparin, Dalteparin Sodium	3
Brand Name	Fragmin®	3
Synonyms	Depo-Heparin, BOXOL, Fraxiparin, Nadroparine, Certoparin, Bemiparin, Adomiparin	6
DrugBank ID	DB06779	1
Drug Type	Small Molecule	2
CAS Number	9005-49-6 (Dalteparin); 9041-08-1 (Dalteparin Sodium)	1
UNII	12M44VTJ7B; S79O08V79F	1
ATC Code	B01AB04	3
Molecular Formula	C26H42N2O37S5 (representative structure)	9
Molecular Weight	~1134.89 g/mol (representative structure); average 5000 Da (mixture)	1
Legal Status	Australia: S4 (Prescription only); United States: ℞-only	3

Pharmacology: Mechanism of Action and Pharmacodynamic Effects

Potentiation of Antithrombin and Inhibition of Coagulation Factors

The fundamental mechanism of action of dalteparin is its ability to potentiate the activity of antithrombin (AT, or ATIII), a serine protease inhibitor that is a key endogenous regulator of the coagulation cascade.[3] Dalteparin contains a unique pentasaccharide sequence that binds with high affinity to antithrombin.[1] This binding induces a critical conformational change in the antithrombin molecule, which dramatically accelerates its rate of inactivation of several activated coagulation factors, most notably Factor Xa and Factor IIa (thrombin).[3] By inhibiting these key enzymes, dalteparin effectively blocks the propagation of the coagulation cascade, preventing the conversion of prothrombin to thrombin and the subsequent conversion of fibrinogen to fibrin, which is the structural basis of a blood clot.[11]

Preferential Activity on Factor Xa vs. Factor IIa

A defining pharmacodynamic feature of dalteparin, and LMWHs in general, is its preferential inhibitory activity against Factor Xa as compared to thrombin.[1] The ratio of anti-Factor Xa to anti-Factor IIa activity for dalteparin is approximately

2.7:1, a stark contrast to the 1:1 ratio observed with UFH.[13]

This selectivity is a direct consequence of dalteparin's smaller molecular size. To inactivate Factor Xa, only the binding of the heparin-antithrombin complex is required. However, the inactivation of thrombin requires the formation of a ternary complex, where the heparin molecule must bridge both antithrombin and thrombin simultaneously. The shorter polysaccharide chains of dalteparin are less capable of forming this ternary bridge efficiently, resulting in a much weaker anti-thrombin effect relative to its potent anti-Factor Xa activity.

This specific molecular behavior has profound clinical implications. The shift from balanced anti-IIa/anti-Xa activity in UFH to preferential anti-Xa activity in dalteparin is the direct cause of a paradigm shift in the clinical management of thrombosis. Because dalteparin has a less pronounced effect on thrombin, it does not significantly prolong the activated partial thromboplastin time (aPTT) at standard therapeutic doses.[12] This renders the aPTT test, the cornerstone of UFH monitoring, unreliable for assessing dalteparin's therapeutic effect.[1] This, in turn, obviates the need for frequent blood draws and dose adjustments, which are characteristic of UFH therapy. The predictable dose-response relationship, driven by reliable anti-Xa activity, allows for simple weight-based subcutaneous dosing regimens.[12] This simplification has been instrumental in facilitating the transition of VTE treatment from a mandatory inpatient setting, with its associated costs and burdens, to a more convenient and cost-effective outpatient model.[5] Thus, a specific molecular interaction has cascaded into effects that have reshaped the entire clinical and economic landscape of anticoagulant therapy.

Comparative Pharmacodynamics: Dalteparin vs. Unfractionated Heparin (UFH)

The pharmacodynamic profile of dalteparin differs from that of UFH in several clinically important ways beyond its anti-Xa selectivity.

• Therapeutic Monitoring: As noted, the aPTT is not a suitable measure of dalteparin's anticoagulant effect and should only be used as a qualitative indicator of potential overdosage.[12] The anticoagulant activity of dalteparin is quantified by measuring plasma anti-Factor Xa levels, with its potency expressed in international anti-Xa units (IU).[2] However, due to its predictable pharmacokinetics, even anti-Xa monitoring is not routinely required for most patient populations.[16]
• Platelet Interaction and HIT: Dalteparin exhibits a reduced interaction with platelets and platelet factor 4 (PF4) compared to UFH. This results in a smaller effect on platelet function and adhesion and, critically, a significantly lower incidence of heparin-induced thrombocytopenia (HIT), a life-threatening immune-mediated complication of heparin therapy.[1]
• Other Effects: Dalteparin is associated with smaller increases in plasma free fatty acids and lipoprotein lipase activity than UFH.[12] It can cause a transient, reversible elevation of liver transaminases (aminotransferases), an effect that occurs to a similar extent as with UFH.[2]

Additional Molecular Targets

Beyond its established role in the coagulation cascade, dalteparin has been identified as having inhibitory activity against other biological targets. These include Vascular Endothelial Growth Factor A (VEGF-A) and P-selectin.[2] While the clinical significance of these interactions is not fully elucidated, the inhibition of VEGF-A, a key mediator of angiogenesis, has generated interest regarding potential ancillary benefits in the context of cancer treatment.

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

Absorption and Bioavailability

Following subcutaneous (SC) administration, dalteparin is well and almost completely absorbed. Its absolute bioavailability, as measured by anti-Factor Xa activity, is high and predictable, averaging 87% with a range of 81% to 93%.[1] This represents a marked improvement over UFH, whose SC bioavailability is poor and erratic.

Peak plasma concentrations (Cmax​) of anti-Factor Xa activity are typically achieved 3 to 4 hours after a subcutaneous injection.[16] In patients on a twice-daily dosing regimen, steady-state plasma levels are attained after approximately 2 to 4 injections (24 to 48 hours).[12] A key feature of dalteparin's pharmacokinetics is the direct and predictable relationship between the administered dose and the resulting plasma anti-Factor Xa activity, which underpins the reliability of weight-based dosing without routine monitoring.[12]

Volume of Distribution (Vd)

Dalteparin has a relatively small volume of distribution, approximately 3 liters or 40-60 mL/kg in adults.[1] This indicates that the drug is primarily confined to the intravascular and extracellular fluid compartments and does not distribute extensively into tissues. Animal studies have shown that the distribution pattern is similar regardless of whether the dose is administered intravenously or subcutaneously.[12] Critically for its use in obstetrics, dalteparin does not cross the placental barrier, preventing direct fetal exposure.[13]

Metabolism

Dalteparin undergoes partial metabolism, primarily occurring in the liver and the reticuloendothelial system.[2] The metabolic pathways involve desulphatation and depolymerization, breaking down the larger polysaccharide chains into smaller, less active fragments.[2]

Elimination and Excretion

The primary route of elimination for dalteparin and its metabolites is renal excretion.[1] Animal studies indicate that approximately 70% of an administered dose is cleared via the kidneys.[1] The plasma clearance rate in adults is approximately 33 mL/min.[1] Unlike UFH, which is cleared by a saturable, dose-dependent mechanism involving the reticuloendothelial system, dalteparin's clearance is predominantly non-saturable and renal-dependent. This difference contributes significantly to its more predictable dose-response and longer half-life.

Biological Half-Life (t1/2​)

The elimination half-life of dalteparin is substantially longer than that of UFH. Following intravenous administration, the half-life is approximately 2.1 to 2.3 hours.[3] After subcutaneous administration, the apparent half-life is prolonged to 3 to 5 hours.[2] This longer duration is likely due to a "flip-flop" pharmacokinetic phenomenon, where the rate of absorption from the subcutaneous depot is slower than the rate of elimination, making absorption the rate-limiting step. This extended half-life is what allows for convenient once or twice-daily dosing regimens.

The reliance on renal clearance means that the half-life can be significantly affected by kidney function. In patients with severe chronic renal insufficiency requiring hemodialysis, the terminal half-life of anti-Xa activity has been shown to be prolonged to approximately 5.7 hours, indicating a substantial risk of drug accumulation with repeated dosing.[17] This observation has led to a nuanced clinical understanding of dalteparin's use in renal impairment. While some early literature, based on studies using lower prophylactic doses in critically ill patients, suggested that dalteparin does not accumulate significantly even with reduced kidney function [3], this finding does not hold true for all clinical scenarios. The risk of clinically significant accumulation is a function of both the degree of renal impairment and the total drug exposure (dose and duration). At lower prophylactic doses (e.g., 5000 IU daily), accumulation in mild-to-moderate renal insufficiency may be subclinical and not necessitate dose adjustments.[11] However, at higher therapeutic doses (e.g., 200 IU/kg daily) used for VTE treatment, particularly over extended periods in cancer patients, the same degree of renal impairment can lead to dangerous accumulation and an increased risk of bleeding. This reality is reflected in current FDA labeling and clinical guidelines, which recommend cautious use, anti-Xa level monitoring, and potential dose adjustments in patients with severe renal impairment (Creatinine Clearance [CrCl] <30 mL/min).[1] This distinction is vital for ensuring the safe clinical application of the drug.

The following table summarizes the key pharmacokinetic parameters of dalteparin.

Table 2: Key Pharmacokinetic Parameters of Dalteparin

Parameter	Value / Range	Clinical Significance / Notes	Source(s)
Bioavailability (SC)	81-93% (mean 87%)	High and predictable bioavailability allows for reliable subcutaneous dosing without the need for IV administration for most indications.	2
Time to Peak Plasma Concentration (Tmax​)	3-4 hours (SC)	The delay to peak effect must be considered when timing administration relative to invasive procedures.	16
Volume of Distribution (Vd​)	~3 L (40-60 mL/kg)	Primarily confined to the bloodstream; does not cross the placenta, making it a preferred agent in pregnancy.	1
Elimination Half-Life (t1/2​)	~2.1-2.3 hours (IV); 3-5 hours (SC)	The longer half-life after subcutaneous injection supports convenient once or twice-daily dosing regimens.	2
Primary Route of Elimination	Renal (~70%)	Clearance is dependent on kidney function; risk of accumulation in severe renal impairment.	1
Plasma Clearance	~33 mL/min	Reflects a non-saturable elimination process, contributing to a predictable dose-response.	1

Clinical Applications and Efficacy

A. FDA-Approved Indications

Dalteparin has received approval from the U.S. Food and Drug Administration (FDA) for a range of indications related to the prevention and treatment of thromboembolic disease.[7]

• Prophylaxis of Venous Thromboembolism (VTE): Dalteparin is indicated for the prevention of DVT, which can lead to PE, in several high-risk patient populations:
• Patients Undergoing Abdominal Surgery: For individuals identified as being at risk for postoperative thromboembolic complications.[1]
• Patients Undergoing Hip Replacement Surgery: This major orthopedic procedure carries a very high intrinsic risk of VTE, and dalteparin is a standard agent for prophylaxis in this setting.[17]
• Acutely Ill Medical Patients: For hospitalized patients whose mobility is severely restricted during an acute illness, placing them at increased risk for VTE.[17]
• Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave Myocardial Infarction (NSTEMI): In the setting of acute coronary syndromes, dalteparin is indicated for use concurrently with aspirin therapy to reduce the risk of death or subsequent myocardial infarction.[2]
• Extended Treatment of Symptomatic VTE in Adult Patients with Cancer: Dalteparin is approved for the extended treatment (up to six months) of symptomatic VTE (proximal DVT and/or PE) to reduce the risk of recurrence in adult patients with cancer.[17] This indication is strongly supported by the landmark CLOT trial, published in 2003. This study demonstrated that dalteparin was significantly more effective than the oral vitamin K antagonist warfarin in reducing the risk of recurrent VTE in this challenging, high-risk population, without a significant increase in major bleeding.[3]
• Treatment of Symptomatic VTE in Pediatric Patients: In May 2019, the FDA approved dalteparin to treat symptomatic VTE and reduce the risk of recurrence in pediatric patients one month of age and older.[3] This was a critical approval, making it the first anticoagulant specifically sanctioned for this use in this vulnerable population.

The approval and subsequent widespread adoption of dalteparin for cancer-associated thrombosis (CAT) marked a fundamental advancement in oncology supportive care. VTE is a leading cause of morbidity and mortality in cancer patients, a risk compounded by the prothrombotic effects of many chemotherapeutic agents.[27] Traditional anticoagulation with warfarin proved to be suboptimal in this population due to numerous challenges, including frequent drug-drug interactions with chemotherapy agents, difficulty in maintaining a stable International Normalized Ratio (INR), and a paradoxically high rate of both recurrent VTE and major bleeding.[27] The CLOT trial provided definitive, level-1 evidence that LMWH therapy with dalteparin was superior to warfarin for preventing VTE recurrence in CAT patients.[3] This pivotal finding led to a rapid change in major clinical practice guidelines, establishing LMWH as the standard of care for the initial and extended treatment of CAT.[27] This has firmly integrated thrombosis management as a core competency within oncologic practice, underscoring the critical interplay between malignancy and hemostasis.

B. Off-Label and Investigational Uses

Beyond its FDA-approved indications, dalteparin is used in a number of important off-label clinical scenarios, often supported by clinical practice guidelines and extensive clinical experience.

• Anticoagulation in Pregnancy: LMWHs, including dalteparin, are the anticoagulants of choice for the management of VTE during pregnancy. Because they do not cross the placenta, they do not pose a risk of fetal anticoagulation or teratogenicity.[13] They are used off-label for both VTE prophylaxis and treatment in pregnant women with conditions such as inherited thrombophilias, a personal history of VTE, antiphospholipid syndrome, or prosthetic heart valves.[23]
• Bridging Therapy: Dalteparin is commonly used as a "bridge" to provide immediate anticoagulation while a slower-acting oral anticoagulant, such as warfarin, reaches its therapeutic effect. It is also used to cover periods when oral anticoagulants must be temporarily discontinued for invasive procedures.[23]
• Atrial Fibrillation and Prosthetic Heart Valves: While direct oral anticoagulants and warfarin are primary therapies, dalteparin may be used for thromboprophylaxis in patients with atrial fibrillation or mechanical prosthetic heart valves, particularly as a bridging agent or when oral therapies are contraindicated.[19]
• Other Surgical Prophylaxis: Clinical practice guidelines support the use of LMWH for VTE prophylaxis in other high-risk surgical settings, including total knee replacement, hip fracture surgery, neurosurgery, and major thoracic surgery.[17]
• Other Medical and Critical Care Conditions: Dalteparin is used to prevent clotting in extracorporeal circuits during hemodialysis and hemofiltration.[1] It is also recommended for thromboprophylaxis in critically ill patients in the intensive care unit (ICU), major trauma patients, and select patients with acute ischemic stroke who are at high risk for VTE.[17]

Dosage, Administration, and Therapeutic Monitoring

General Administration Guidelines and Formulations

Dalteparin is formulated as a sterile solution for injection. The primary route of administration for most indications is subcutaneous (SC) injection.[3] It is imperative that dalteparin

not be administered via the intramuscular (IM) route, as this carries a high risk of causing a painful and potentially large hematoma.[22] For the indication of preventing clotting in extracorporeal circuits during hemodialysis, it may also be administered intravenously (IV).[16]

The potency of dalteparin is standardized and expressed in international anti-Factor Xa units (IU).[12] It is available in a variety of presentations to accommodate different dosing needs, including single-dose prefilled syringes at strengths such as 2,500 IU, 5,000 IU, 7,500 IU, 10,000 IU, 12,500 IU, 15,000 IU, and 18,000 IU, as well as multi-dose vials.[22] Patients receiving dalteparin on an outpatient basis should be instructed on proper injection technique, including rotating injection sites between the left and right anterolateral and posterolateral abdominal wall to minimize local skin reactions and bruising.[20]

Indication-Specific Dosing Regimens

Dalteparin dosing is highly specific to the clinical indication, patient body weight, and in some cases, specific risk factors such as malignancy or renal function. The following table provides a consolidated guide to dosing for major indications in both adult and pediatric populations.

Table 3: Comprehensive Dosing Guide for Dalteparin

Indication	Patient Population	Dosing Regimen (Dose, Frequency, Duration)	Maximum Dose	Key Clinical Notes	Source(s)
VTE Prophylaxis (Abdominal Surgery)	Adult (Moderate Risk)	2,500 IU SC once daily, starting 1-2 hours pre-op. Duration: 5-10 days.	N/A		15
	Adult (High Risk)	5,000 IU SC once daily, starting evening before surgery. Duration: 5-10 days.	N/A	Alternative regimens exist.	15
VTE Prophylaxis (Hip Replacement)	Adult	Various regimens (pre-op, post-op start). Typically 2,500 IU or 5,000 IU SC, progressing to 5,000 IU SC once daily. Duration: 5-10 days, up to 35 days.	N/A	Timing relative to surgery is critical.	15
VTE Prophylaxis (Acutely Ill Medical)	Adult	5,000 IU SC once daily. Duration: 12-14 days.	N/A	For patients with severely restricted mobility.	15
Unstable Angina / NSTEMI	Adult	120 IU/kg SC every 12 hours. Duration: 5-8 days (until clinically stable).	10,000 IU per dose	Must be given with concurrent oral aspirin (75-165 mg/day).	15
Extended Treatment of VTE in Cancer	Adult	Month 1: 200 IU/kg SC once daily. Months 2-6: 150 IU/kg SC once daily.	18,000 IU per day	Dosing is based on weight brackets. Monitor anti-Xa in severe renal impairment.	15
Treatment of VTE (Pediatrics)	8 to <17 years	100 IU/kg SC twice daily.	N/A	Dose adjustment based on anti-Xa levels is recommended.	17
	2 to <8 years	125 IU/kg SC twice daily.	N/A	Dose adjustment based on anti-Xa levels is recommended.	17
	1 month to <2 years	150 IU/kg SC twice daily.	N/A	Dose adjustment based on anti-Xa levels is recommended.	17
Hemodialysis / Hemofiltration	Adult	IV bolus (e.g., 5,000 IU) or weight-based bolus plus infusion (e.g., 30-40 IU/kg bolus, then 10-15 IU/kg/hr).	N/A	Dose adjusted based on outcome of previous dialysis session.	11

Dose Adjustments for Special Conditions

• Renal Impairment: For patients with severe renal impairment (CrCl <30 mL/min) receiving therapeutic doses (e.g., for CAT), dose adjustments are necessary. The FDA recommends monitoring anti-Xa levels to guide dosing, with a target peak level (drawn 4-6 hours post-dose) between 0.5 and 1.5 IU/mL.[15]
• Thrombocytopenia: In the setting of VTE treatment in cancer patients, dose modification is required for thrombocytopenia. If the platelet count falls to between 50,000 and 100,000/mm³, the daily dose should be reduced. If the platelet count falls below 50,000/mm³, dalteparin therapy should be interrupted until the count recovers.[15]

Role of Anti-Factor Xa Monitoring

Routine coagulation monitoring is generally not required for the majority of patients receiving dalteparin, a key advantage stemming from its predictable pharmacokinetic profile.[15] However, monitoring of peak anti-Factor Xa levels (achieved by drawing a blood sample 3 to 4 hours after a subcutaneous dose) should be strongly considered in specific patient populations where pharmacokinetics may be altered and unpredictable. These populations include:

• Patients with severe renal impairment (CrCl <30 mL/min)
• Patients with morbid obesity
• Pregnant patients
• All pediatric patients.[16]

Safety Profile: Warnings, Adverse Reactions, and Contraindications

A. FDA Black Box Warning: Spinal/Epidural Hematomas

Dalteparin carries a Black Box Warning from the FDA, the most serious level of warning, regarding the risk of spinal or epidural hematomas.[13]

• The Warning: The FDA warns that epidural or spinal hematomas may occur in patients who are anticoagulated with LMWHs, including dalteparin, and are concurrently receiving neuraxial anesthesia (e.g., epidural or spinal anesthesia) or are undergoing spinal puncture. These hematomas are a rare but catastrophic complication that can result in long-term or permanent paralysis.[22]
• Risk Factors: The risk of this complication is increased by several factors:
• The use of indwelling epidural catheters for postoperative pain management.
• The concomitant use of other medications that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors (e.g., clopidogrel, aspirin), and other anticoagulants.
• A history of traumatic or repeated epidural or spinal punctures.
• A history of spinal deformity or prior spinal surgery.[17]
• Management and Mitigation: This risk is not merely a precaution but a critical safety issue that necessitates a system-level approach to patient management. The potential for a "never event" like permanent paralysis forces a mandatory, interdisciplinary dialogue between surgical, anesthesia, and medical teams to carefully weigh the risk of thrombosis against the risk of catastrophic neurological injury. This has led to the widespread implementation of institutional protocols, safety checklists, and procedural "time-outs" that specifically address anticoagulation management in the setting of neuraxial procedures. Clinicians must maintain a high index of suspicion and monitor patients frequently for any signs or symptoms of neurological impairment, such as new-onset back pain, sensory or motor deficits (numbness, tingling, muscle weakness, especially in the legs and feet), or bowel and bladder dysfunction.[30] If neurological compromise is suspected, urgent diagnosis and surgical decompression are required to mitigate the potential for permanent damage.

B. Contraindications

The use of dalteparin is strictly contraindicated in the following situations [13]:

• Presence of active major bleeding.
• A history of confirmed or suspected immunologically-mediated heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia with thrombosis (HITT).
• Known hypersensitivity to dalteparin, unfractionated heparin, pork products, or any other component in the formulation.
• In patients undergoing neuraxial anesthesia, the use of dalteparin for the treatment of unstable angina/NSTEMI or for prolonged VTE prophylaxis is contraindicated due to the heightened risk of spinal hematoma.

C. Major Warnings and Precautions

• Hemorrhage: Bleeding is the most common and predictable major complication of dalteparin therapy. It can occur at any site. Extreme caution must be exercised when using dalteparin in patients with pre-existing conditions that increase bleeding risk, such as congenital or acquired bleeding disorders, active gastroduodenal ulcers, severe uncontrolled hypertension, recent brain, spine, or ophthalmologic surgery, or hemorrhagic stroke.[21]
• Heparin-Induced Thrombocytopenia (HIT): Although the risk is lower with LMWHs than with UFH, dalteparin can still trigger HIT, a serious prothrombotic condition mediated by antibodies to the heparin-PF4 complex. Platelet counts should be monitored periodically during therapy. If a patient develops new thrombosis or if the platelet count falls significantly (e.g., below 100,000/mm³), HIT should be suspected, and dalteparin must be discontinued immediately.[6]
• Benzyl Alcohol Preservative: The multi-dose vial formulation of dalteparin contains benzyl alcohol as a preservative. This substance has been associated with a fatal "gasping syndrome" in premature infants and neonates. Therefore, multi-dose vials are contraindicated for use in neonates, infants, and pregnant women. Preservative-free single-dose syringes should be used in these populations.[13]

D. Adverse Drug Reactions

• Common (>1% incidence): The most frequently reported adverse reactions include minor bleeding manifestations (bruising, epistaxis), hematoma and pain at the injection site, and a transient, asymptomatic elevation of liver transaminases (ALT/AST).[2] A mild, non-immune, transient thrombocytopenia (Type I HIT) can also occur.
• Serious/Uncommon: Serious adverse reactions include major hemorrhage (which can be retroperitoneal, intracranial, or gastrointestinal), severe immune-mediated HIT (Type II), anaphylactoid reactions and other hypersensitivity events (rash, urticaria, angioedema), skin necrosis at the injection site, and hyperkalemia (due to aldosterone suppression). Osteopenia and osteoporosis have been reported with prolonged, long-term use of heparins.[2]

E. Overdose Management

An overdose of dalteparin manifests as hemorrhagic complications, ranging from minor bruising to life-threatening bleeding.[1]

• Antidote: The anticoagulant effect of dalteparin can be partially reversed by the administration of protamine sulfate.[13]
• Dosing and Administration: Protamine sulfate should be administered via a slow intravenous injection. The recommended dose is 1 mg of protamine for every 100 anti-Xa IU of dalteparin that was administered. If bleeding persists, a second, smaller infusion of 0.5 mg of protamine per 100 IU of dalteparin may be considered.[41]
• Limitations: It is crucial to understand that protamine is only a partial antidote. While it can largely neutralize the anti-thrombin (anti-IIa) activity of dalteparin, it only ever neutralizes the anti-Factor Xa activity by a maximum of about 60%. Furthermore, protamine sulfate carries its own significant risks, including the potential for severe hypotensive and anaphylactoid reactions. It should only be administered in a setting where resuscitation equipment is readily available.[41]

Drug and Food Interactions

Interactions with Drugs Affecting Hemostasis (Pharmacodynamic Synergism)

The most significant and dangerous drug interactions with dalteparin are those that involve pharmacodynamic synergism, where concomitant use of another agent that impairs hemostasis dramatically increases the risk of bleeding.[4] Co-administration of these agents should be done with extreme caution, if at all, and requires intensified clinical monitoring for signs of hemorrhage.

• Other Anticoagulants: Concurrent use with vitamin K antagonists (e.g., warfarin), direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and dabigatran, or other heparins (unfractionated or other LMWHs like enoxaparin) will produce an additive anticoagulant effect and substantially elevate bleeding risk.[23]
• Platelet Inhibitors: Medications that inhibit platelet function, including aspirin, P2Y12 inhibitors (e.g., clopidogrel, prasugrel, ticagrelor), dipyridamole, and glycoprotein IIb/IIIa inhibitors, will increase bleeding risk when used with dalteparin.[23]
• Nonsteroidal Anti-inflammatory Drugs (NSAIDs): NSAIDs (e.g., ibuprofen, naproxen, ketorolac, diclofenac) inhibit platelet function and can cause gastrointestinal ulceration, both of which increase the risk of bleeding when combined with an anticoagulant.[11]
• Thrombolytic Agents: Co-administration with thrombolytics (e.g., alteplase) is generally contraindicated outside of specific, highly monitored protocols (e.g., for STEMI) due to a very high risk of major hemorrhage.[22]
• Contraindicated Combinations: The use of dalteparin with defibrotide or mifepristone is contraindicated due to an unacceptably high risk of life-threatening hemorrhage.[13]

Other Clinically Significant Drug Interactions

• Potassium-Sparing Drugs: Dalteparin can suppress aldosterone secretion, potentially leading to hyperkalemia. This effect can be additive with other drugs that increase serum potassium, such as ACE inhibitors, angiotensin II receptor blockers (ARBs), and potassium-sparing diuretics (e.g., spironolactone). Serum potassium should be monitored in at-risk patients receiving these combinations.[4]

Potential Food, Alcohol, and Herbal Interactions

While formal drug-food interaction studies have not established definitive contraindications, caution is advised based on theoretical mechanisms and anecdotal reports.[43]

• Alcohol: Consumption of alcohol may increase the risk of gastrointestinal bleeding, which would be exacerbated by dalteparin's anticoagulant effect.[44]
• Herbal Supplements: Patients should be advised to use caution with herbal products and supplements known to possess anticoagulant or antiplatelet properties, as these could synergistically increase bleeding risk. Examples include garlic, ginkgo biloba, ginseng, and St. John's wort.[44]
• Foods and Juices: Some sources suggest potential interactions with certain juices (cranberry, grapefruit, pomegranate) and vitamin K-rich foods (e.g., leafy greens), though the clinical significance of these interactions with dalteparin is not well-established and is likely minimal compared to the impact on warfarin.[44]

Use in Specific Patient Populations

Pregnancy and Lactation

• Pregnancy: Dalteparin is a preferred anticoagulant for use during pregnancy when an indication exists. Crucially, it does not cross the placental barrier, thereby avoiding fetal anticoagulation.[13] Its use is supported by clinical guidelines for managing VTE in pregnant women.[23] However, it is imperative to use preservative-free formulations (single-dose syringes), as the benzyl alcohol contained in multi-dose vials is contraindicated due to the risk of "gasping syndrome" in the neonate and potential harm to the mother.[13] It should be noted that the physiological changes of pregnancy (e.g., increased volume of distribution and glomerular filtration rate) may alter dalteparin pharmacokinetics, and dose monitoring with anti-Xa levels may be necessary in some cases.[13] Dalteparin is assigned an Australian pregnancy category of C.[3]
• Lactation: While data are limited, small amounts of dalteparin may be distributed into human milk. However, due to its poor oral bioavailability, significant absorption and anticoagulant effect in the infant are considered unlikely. The potential benefits of maternal treatment should be weighed against any potential risks to the infant.[26]

Pediatric Use

Dalteparin is FDA-approved for the treatment of symptomatic VTE in pediatric patients aged one month and older.[3] The pharmacokinetics of dalteparin are known to change with age; clearance decreases and half-life increases as a child gets older.[13] Consequently, dosing is highly weight-based and stratified by age group (e.g., 1 month to <2 years, 2 to <8 years, 8 to <17 years).[17] Due to this variability, monitoring of anti-Xa levels is generally recommended to ensure therapeutic dosing in this population.[14] As with pregnant patients, benzyl alcohol-containing formulations are strictly contraindicated in neonates and infants.[13]

Geriatric Use

Clinical studies have not shown overall differences in the efficacy of dalteparin between geriatric and younger patients.[13] However, the risk of bleeding may be increased in older adults, particularly those with age-related declines in renal function or low body weight (<45 kg).[22] Therefore, cautious use and careful attention to dosing and concomitant medications are warranted in this population.

Patients with Renal or Hepatic Impairment

• Renal Impairment: Since dalteparin is primarily cleared by the kidneys, its use in patients with severe renal impairment (CrCl <30 mL/min) presents a significant challenge. The elimination half-life is prolonged, leading to a risk of drug accumulation and an increased risk of major bleeding.[20] For patients with severe renal impairment receiving therapeutic doses, dose adjustment and/or monitoring of anti-Xa levels is considered mandatory to ensure safety.[1]
• Hepatic Impairment: Dalteparin is partially metabolized by the liver. While specific dosing guidelines are not well-defined, caution should be exercised in patients with severe hepatic impairment, as drug accumulation and an increased risk of bleeding may occur.[21]

Obese Patients

Standard weight-based dosing may not be optimal in patients with morbid obesity (BMI ≥40 kg/m²). There is a risk of both under-dosing (if capping doses) and over-dosing. There is no clear consensus, but many experts and guidelines suggest that monitoring of anti-Xa levels may be warranted to ensure therapeutic efficacy and safety in this population.[20]

Patients with Cancer

Patients with cancer represent a core population for dalteparin therapy. It is established as the preferred agent for the extended treatment of CAT, based on the superior efficacy demonstrated in the CLOT trial compared to warfarin.[3] Dosing is weight-based, but special consideration must be given to thrombocytopenia, which is a frequent complication of both the malignancy and its treatment. Specific protocols for dose reduction or interruption based on platelet counts are essential for safe use.[15]

Conclusion and Clinical Recommendations

Dalteparin sodium is a cornerstone of modern anticoagulant therapy. As a low molecular weight heparin, it offers a significantly improved pharmacokinetic and safety profile compared to its predecessor, unfractionated heparin, allowing for predictable, weight-based subcutaneous dosing with minimal need for routine monitoring in most patients. Its efficacy is well-established across a broad spectrum of clinical applications, including the prophylaxis of VTE in surgical and medical patients, the management of acute coronary syndromes, and the treatment of established VTE. Its most notable role is as the guideline-supported standard of care for the extended treatment of cancer-associated thrombosis, a paradigm established by landmark clinical evidence.

For the optimal and safe use of dalteparin in clinical practice, the following key considerations are paramount:

1. Rigorous Patient Selection: Clinicians must carefully assess each patient for contraindications, particularly active bleeding, a history of HIT, and known hypersensitivity. A thorough evaluation of the patient's intrinsic bleeding risk is essential before initiating therapy.
2. Adherence to the Black Box Warning: The risk of spinal or epidural hematoma in patients undergoing neuraxial procedures is a critical, albeit rare, safety issue. Strict adherence to institutional protocols regarding the timing of dalteparin administration relative to spinal puncture or catheter placement/removal is mandatory. Vigilant neurological monitoring in the post-procedural period is essential to detect this catastrophic complication early.
3. Accurate Dosing and Administration: Dosing must be precise and based on the specific indication and patient body weight. Special attention is required for dosing in cancer patients and pediatric populations. Patients and caregivers must be educated on the correct technique for subcutaneous administration to ensure efficacy and minimize local adverse effects.
4. Targeted Therapeutic Monitoring: While routine monitoring is unnecessary for most, clinicians must identify the specific high-risk populations in whom monitoring of anti-Factor Xa levels is warranted. This includes patients with severe renal impairment (CrCl <30 mL/min), morbid obesity, pregnancy, and pediatric patients.
5. Comprehensive Patient Education: Effective patient counseling is a critical component of safe dalteparin therapy. Patients must be educated to recognize the signs and symptoms of bleeding (from minor bruising to major hemorrhage) and the neurological signs of a potential spinal hematoma. They must understand the importance of seeking immediate medical attention if such symptoms occur. They should also be counseled on potential drug and herbal interactions that could increase their risk of bleeding.

By integrating these principles into clinical practice, healthcare providers can leverage the substantial therapeutic benefits of dalteparin while minimizing its inherent risks, ensuring optimal outcomes for patients with or at risk for thromboembolic disease.

Works cited

1. Dalteparin - PubChem, accessed July 26, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Dalteparin
2. Dalteparin: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 26, 2025, https://go.drugbank.com/drugs/DB06779
3. Dalteparin sodium - Wikipedia, accessed July 26, 2025, https://en.wikipedia.org/wiki/Dalteparin_sodium
4. dalteparin injection (Fragmin) Uses, Side Effects & Dosage - MedicineNet, accessed July 26, 2025, https://www.medicinenet.com/dalteparin_injection/article.htm
5. Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders - PubMed, accessed July 26, 2025, https://pubmed.ncbi.nlm.nih.gov/8841743/
6. Dalteparin Sodium - Protheragen, accessed July 26, 2025, https://www.protheragen.ai/dalteparin-sodium-item-11617.html
7. Fragmin (dalteparin sodium) FDA Approval History - Drugs.com, accessed July 26, 2025, https://www.drugs.com/history/fragmin.html
8. Heparin | Thrombin | Antibacterial | Endogenous Metabolite - TargetMol, accessed July 26, 2025, https://www.targetmol.com/compound/heparin
9. Heparin | CAS#9005-49-6 | anticoagulant - MedKoo Biosciences, accessed July 26, 2025, https://www.medkoo.com/products/25463
10. Heparin | 9005-49-6 | YH03833 - Biosynth, accessed July 26, 2025, https://www.biosynth.com/p/YH03833/9005-49-6-heparin
11. Dalteparin - Mechanism, Indication, Contraindications, Dosing ..., accessed July 26, 2025, https://www.pediatriconcall.com/drugs/dalteparin/460
12. FRAGMIN (dalteparin sodium) 10 Clinical Pharmacology | Pfizer Medical Information, accessed July 26, 2025, https://www.pfizermedicalinformation.ca/fragmin/10-clinical-pharmacology
13. Dalteparin - StatPearls - NCBI Bookshelf, accessed July 26, 2025, https://www.ncbi.nlm.nih.gov/books/NBK603711/
14. Dalteparin - WikEM, accessed July 26, 2025, https://wikem.org/wiki/Dalteparin
15. Dalteparin Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed July 26, 2025, https://www.drugs.com/dosage/dalteparin.html
16. Dalteparin Sodium Injection FRAGMIN - Pfizer, accessed July 26, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=15035
17. Dalteparin Monograph for Professionals - Drugs.com, accessed July 26, 2025, https://www.drugs.com/monograph/dalteparin.html
18. Pharmacokinetics of dalteparin and nadroparin for thromboses in children with oncological diseases - MedCrave online, accessed July 26, 2025, https://medcraveonline.com/HTIJ/pharmacokinetics-of-dalteparin-and-nadroparin-for-thromboses-in-children-with-oncological-diseases.html
19. Study Details | A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery | ClinicalTrials.gov, accessed July 26, 2025, https://clinicaltrials.gov/study/NCT00260988
20. What is the therapeutic dosing for Dalteparin (Fragmin)? - Dr.Oracle AI, accessed July 26, 2025, https://www.droracle.ai/articles/90789/what-is-the-therapeutic-dosing-for-dalteparin-fragmin
21. Dalteparin: Drug information - sniv3r2.github.io, accessed July 26, 2025, https://sniv3r2.github.io/d/topic.htm?path=dalteparin-drug-information
22. FRAGMIN® (dalteparin sodium) injection, USP ... - accessdata.fda.gov, accessed July 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020287s080lbl.pdf
23. Clinical Policy: Dalteparin (Fragmin) - PA Health & Wellness, accessed July 26, 2025, https://www.pahealthwellness.com/content/dam/centene/Pennsylvania/policies/pharmacy-policies/PA.CP.PHAR.225%20Dalteparin%20(Fragmin).pdf
24. Clinical Policy: Dalteparin (Fragmin) - Ambetter Health, accessed July 26, 2025, https://www.ambetterhealth.com/content/dam/centene/Superior/policies/pharmacy-policies/Dalteparin%20(Fragmin)%20(CP.PHAR.225)%20(PDF).pdf
25. Reference ID: 4712528 - accessdata.fda.gov, accessed July 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020287Orig1s076lbl.pdf
26. Dalteparin (subcutaneous route) - Side effects & dosage - Mayo Clinic, accessed July 26, 2025, https://www.mayoclinic.org/drugs-supplements/dalteparin-subcutaneous-route/description/drg-20063314
27. Management of venous thromboembolism in patients with cancer: role of dalteparin - PMC, accessed July 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2496976/
28. Dalteparin (Fragmin®) (Amber TLS) - BSW Together, accessed July 26, 2025, https://bswtogether.org.uk/medicines/wp-content/uploads/sites/3/2023/11/Dalteparin-in-CAT-SCA-adding-SFT-Nov-2023-DRAFT.pdf
29. Low-Molecular-Weight Heparin (LMWH) - StatPearls - NCBI Bookshelf, accessed July 26, 2025, https://www.ncbi.nlm.nih.gov/books/NBK525957/
30. Dalteparin Injection: MedlinePlus Drug Information, accessed July 26, 2025, https://medlineplus.gov/druginfo/meds/a696006.html
31. Fragmin (dalteparin) dosing, indications, interactions, adverse effects, and more, accessed July 26, 2025, https://reference.medscape.com/drug/fragmin-dalteparin-342142
32. FRAGMIN (dalteparin sodium) 4 Dosage And Administration | Pfizer Medical Information, accessed July 26, 2025, https://www.pfizermedicalinformation.ca/fragmin/4-dosage-and-administration
33. 1 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsa, accessed July 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020287s072lbl.pdf
34. Dalteparin | Side Effects, Dosage, Uses and More - Healthline, accessed July 26, 2025, https://www.healthline.com/health/drugs/dalteparin-injectable-solution
35. FRAGMIN (dalteparin sodium) 2 Contraindications - Pfizer Medical Information - Canada, accessed July 26, 2025, https://www.pfizermedicalinformation.ca/fragmin/2-contraindications
36. Dalteparin Disease Interactions - Drugs.com, accessed July 26, 2025, https://www.drugs.com/disease-interactions/dalteparin.html
37. Dalteparin: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed July 26, 2025, https://www.rxlist.com/dalteparin/generic-drug.htm
38. Dalteparin Uses, Side Effects & Warnings - Drugs.com, accessed July 26, 2025, https://www.drugs.com/mtm/dalteparin.html
39. What are the side effects of Dalteparin Sodium? - Patsnap Synapse, accessed July 26, 2025, https://synapse.patsnap.com/article/what-are-the-side-effects-of-dalteparin-sodium
40. www.ncbi.nlm.nih.gov, accessed July 26, 2025, https://www.ncbi.nlm.nih.gov/books/NBK603711/#:~:text=Dalteparin%20causes%20less%20hepatic%20and,or%20looks%20like%20coffee%20grounds.
41. FRAGMIN (dalteparin sodium) 5 Overdosage | Pfizer Medical ..., accessed July 26, 2025, https://www.pfizermedicalinformation.ca/fragmin/5-overdosage
42. Dalteparin Interactions Checker - Drugs.com, accessed July 26, 2025, https://www.drugs.com/drug-interactions/dalteparin.html
43. FRAGMIN (dalteparin sodium) 9 Drug Interactions - Pfizer Medical Information - Canada, accessed July 26, 2025, https://www.pfizermedicalinformation.ca/fragmin/9-drug-interactions
44. Dalteparin: Uses, Side Effects and Medicines | Apollo Pharmacy, accessed July 26, 2025, https://www.apollopharmacy.in/salt/Dalteparin
45. Dalteparin Injection - Cleveland Clinic, accessed July 26, 2025, https://my.clevelandclinic.org/health/drugs/19512-dalteparin-injection
46. Dalteparin Sodium - Pfizer, accessed July 26, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=19703